We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $610M
1-Year Est. Return 40.86%
This Fund
S&P 500
This Quarter Est. Return
-7.65%
1 Year Est. Return
+40.86%
3 Year Est. Return
+46.17%
5 Year Est. Return
+1.2%
10 Year Est. Return
–
AUM
$362M
AUM Growth
-$44.5M
Cap. Flow
-$4.28M
Cap. Flow %
-1.18%
Top 10 Hldgs %
61.36%
Holding
53
New
8
Increased
13
Reduced
15
Closed
17

Top Buys

Rank Stock Value
1
ACHC icon
Acadia Healthcare
ACHC
+$31M
2
ICLR icon
Icon
ICLR
+$19.8M
3
RCKT icon
Rocket Pharmaceuticals
RCKT
+$14M
4
FOLD
Amicus Therapeutics
FOLD
+$9.56M
5
KURA icon
Kura Oncology
KURA
+$8.92M

Top Sells

Rank Stock Value
1
MCK icon
McKesson
MCK
+$17.7M
2
ACCD
Accolade Inc
ACCD
+$10.8M
3
DXCM icon
DexCom
DXCM
+$10.7M
4
CYTK icon
Cytokinetics
CYTK
+$10.2M
5
ZBH icon
Zimmer Biomet
ZBH
+$9.18M

Sector Composition

Rank Sector Weight
1 Healthcare 98.66%
2 Industrials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LKFT
1
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$28.2M 7.79%
1,025,000
-3,843
-0.4% -$107K
ACHC icon
2
Acadia Healthcare
ACHC
$3.17B
$27.4M 7.58%
692,000
+686,334
+12,113% +$31M
BBIO icon
3
BridgeBio Pharma
BBIO
$16.5B
$27.3M 7.55%
995,000
-91,810
-8% -$2.37M
MGTX icon
4
MeiraGTx Holdings
MGTX
$1.09B
$26.7M 7.39%
4,390,837
-509,733
-10% -$2.99M
ABCL icon
5
AbCellera Biologics
ABCL
$1.62B
$21.5M 5.95%
7,350,000
-1,729,539
-19% -$4.82M
ADCT icon
6
ADC Therapeutics
ADCT
$146M
$18.9M 5.23%
9,515,000
-121,237
-1% -$317K
MIRM icon
7
Mirum Pharmaceuticals
MIRM
$6.89B
$18.7M 5.16%
451,127
-14,698
-3% -$612K
ICLR icon
8
Icon
ICLR
$12.8B
$17.8M 4.93%
+85,000
New +$19.8M
ROIV icon
9
Roivant Sciences
ROIV
$25.2B
$17.7M 4.9%
1,500,000
-221,512
-13% -$2.62M
JANX icon
10
Janux Therapeutics
JANX
$935M
$17.7M 4.88%
329,768
+124,768
+61% +$6.6M
SDGR icon
11
Schrodinger
SDGR
$1.12B
$13.9M 3.84%
720,500
+20,500
+3% +$398K
RCKT icon
12
Rocket Pharmaceuticals
RCKT
$348M
$13.7M 3.78%
1,088,706
+929,337
+583% +$14M
ZYME icon
13
Zymeworks
ZYME
$1.68B
$12M 3.32%
820,000
-97,599
-11% -$1.36M
KURA icon
14
Kura Oncology
KURA
$922M
$11.5M 3.19%
1,325,000
+619,891
+88% +$8.92M
FOLD
15
DELISTED
Amicus Therapeutics
FOLD
$8.67M 2.4%
+920,000
New +$9.56M
ZBH icon
16
Zimmer Biomet
ZBH
$17.7B
$8.45M 2.34%
80,000
-85,602
-52% -$9.18M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.84B
$8.2M 2.27%
620,000
+65,897
+12% +$1.13M
STTK icon
18
Shattuck Labs
STTK
$710M
$8.03M 2.22%
6,638,935
+960,209
+17% +$1.19M
IMVT icon
19
Immunovant
IMVT
$8.09B
$7.57M 2.09%
305,523
-64,477
-17% -$1.83M
BPMC
20
DELISTED
Blueprint Medicines
BPMC
$5.84M 1.62%
67,000
+19,900
+42% +$1.82M
PRTA icon
21
Prothena Corp
PRTA
$458M
$5.79M 1.6%
418,122
-65,345
-14% -$1.03M
LKFT
22
CALL
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.82B
$4.86M 1.34%
+176,900
New +$4.93M
CTMX icon
23
CytomX Therapeutics
CTMX
$705M
$4.02M 1.11%
3,905,000
+882,891
+29% +$950K
HAE icon
24
Haemonetics
HAE
$3.58B
$3.65M 1.01%
46,700
-18,300
-28% -$1.47M
CNC icon
25
Centene
CNC
$31.3B
$3.33M 0.92%
+55,000
New +$3.43M
1
2 3

Similar funds

PL
Pandi LLC Leawood, Kansas $610M AUM 14.97% 1-Year Est. Return
BFC
Blue Fin Capital Warren, Rhode Island $610M AUM 26.46% 1-Year Est. Return
DCM
DGS Capital Management Jersey City, New Jersey $609M AUM 44.78% 1-Year Est. Return
SAM
Strategy Asset Managers Pasadena, California $609M AUM 32.56% 1-Year Est. Return
CBB
Citizens Business Bank Ontario, California $610M AUM 27.86% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
FFWA
FRG Family Wealth Advisors Bellevue, Washington $611M AUM 25.92% 1-Year Est. Return
CIP
Convergence Investment Partners Palm Beach Gardens, Florida $611M AUM 61.48% 1-Year Est. Return

Prosight Management's Q4 2024 Portfolio in Review

As of Q4 2024, Prosight Management held 53 positions worth $362M, down 11% from $406M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

Prosight Management's Q4 2024 filing shows 8 new, 13 increased, 15 reduced and 17 closed positions. Its largest new stake was Icon: 85,000 shares worth $17.8M. The largest sale was McKesson, an estimated $17.7M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 94% a quarter earlier, followed by Industrials.

  • Prosight Management's largest Q4 2024 buy was Icon: 85,000 shares worth $17.8M.
  • Prosight Management added most to Acadia Healthcare in Q4 2024, an estimated $31M increase.
  • Prosight Management's biggest Q4 2024 reduction was Zimmer Biomet, cutting an estimated $9.18M.
  • Prosight Management fully exited McKesson in Q4 2024, selling an estimated $17.7M.
  • Prosight Management's ten largest holdings make up 61% of its $362M portfolio in Q4 2024.
  • Prosight Management opened 8 new positions and closed 17 in Q4 2024.
  • Prosight Management's portfolio value fell 11% quarter-over-quarter to $362M.

Based on Prosight Management's 13F filing for Q4 2024, filed 14 Feb 2025.